In Brief: J&J/Ostex
This article was originally published in The Gray Sheet
Executive Summary
J&J/Ostex: Johnson & Johnson Clinical Diagnostics gains co-exclusive ten-year license "to adapt and distribute" Ostex's first product, the Osteomark bone resorption test, for use on J&J's analyzers. The license applies worldwide except for Japan. Under a separate agreement, J&J also will distribute Ostex-manufactured Osteomark test kits in "several world markets." Osteomark, cleared by FDA on May 8, is a urine test designed to diagnose patients who are losing bone mass at a high rate...